| 1. |
|
|
| 2. |
|
|
| 3. |
- Carlsten, Hans, 1954, et al.
(author)
-
The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus
- 2004
-
In: Int Immunopharmacol. - : Elsevier BV. - 1567-5769. ; 4:12, s. 1515-23
-
Journal article (peer-reviewed)abstract
- Autoimmune, lupus-prone MRL lpr/lpr mice were treated orally with oxo-quinoline-3-carboxamide (ABR-25757), a newly developed immunomodulator. Treatment was initiated in one set of experiment at the age of 10 weeks, before the onset of clinically apparent disease, and in another set at 15 weeks, after the development of established lupus disease. Beneficial therapeutic effects were obtained even when ABR-25757 was administered at the lowest dose tested (7.5 microg/mouse/week) to 15 weeks old mice with established lupus disease. The effects of ABR-25757 on longevity, as well as on development of glomerulonephritis were pronounced and comparable with those of LS-2616, a potent immunomodulator. Administration of ABR-25757 did not significantly alter T cell responses in vivo nor in vitro. In addition, it only marginally suppressed B cell responses measured as frequencies of immunoglobulin secreting cells. By the same token this compound did not affect overall leukocyte content in primary (bone marrow) or secondary (spleen) lymphoid tissues. In contrast, treatment with ABR-25757 up regulated expression of pro-inflammatory transcription factors NF-kappaB and AP-1. These results suggest (a) a potential therapeutic role of ABR-25757 in the treatment of experimental lupus and (b) that the effect of the treatment is mediated by immunodeviation rather than by immunosuppression.
|
|
| 4. |
- Feifel, Raimund, et al.
(author)
-
Interference Quenching of v
- 2002
-
In: Physical Review Letters. ; 89:10, s. 103002-1
-
Journal article (peer-reviewed)
|
|
| 5. |
|
|
| 6. |
- Hellström, Mikael, 1950, et al.
(author)
-
Extracolonic and incidental findings on CT colonography (virtual colonoscopy)
- 2004
-
In: AJR Am J Roentgenol. - 0361-803X. ; 182:3, s. 631-8
-
Journal article (peer-reviewed)abstract
- OBJECTIVE: The objective of our study was to prospectively determine the frequency and clinical importance of extracolonic findings on CT colonography in symptomatic patients. SUBJECTS AND METHODS. One hundred eleven symptomatic patients referred for colonoscopy underwent CT colonography before colonoscopy. Helical CT from the diaphragm to the symphysis was performed with the patient in the supine and prone positions after rectal air insufflation. Image interpretation was done on a digital workstation. Extracolonic findings were classified as minor, moderate, or major according to potential clinical importance. Patient records, with a follow-up time of about 3 years, were reviewed to determine final diagnoses. RESULTS: Twenty-six (23%) of the patients had CT findings of major importance such as lymphadenopathy (n = 7), aortic aneurysm (n = 6), suspected solid hepatic masses (n = 5), and suspected solid renal masses (n = 4). Fifty-eight patients (52%) had findings of moderate importance such as gallstones (n = 16), indeterminate renal masses (n = 9), adrenal masses with benign appearance (n = 8), and hiatal hernia (n = 7). Forty-six patients (41%) had no or only minor findings, such as renal cysts (n = 34), renal calcifications (n = 19), and hepatic cysts (n = 14). Review of patient records showed that CT colonography contributed to the detection of major, previously unknown extracolonic disorders in 14 (13%) of the 111 patients. CONCLUSION: Potentially important extracolonic findings were revealed in 23% of the patients, leading to additional diagnostic or therapeutic considerations. Some of these findings were clinically important, whereas others were previously known or led to unnecessary workup. This finding must be taken into account when CT colonography is considered for routine diagnostic workup or screening.
|
|
| 7. |
- Johnson, Magnus S.C. 1969, et al.
(author)
-
Interaction of scavenger receptor class B type I with peroxisomal targeting receptor Pex5p.
- 2003
-
In: Biochemical and biophysical research communications. - 0006-291X. ; 312:4, s. 1325-34
-
Journal article (peer-reviewed)abstract
- Scavenger receptor class B type I (SR-BI) is an HDL receptor that mediates selective HDL lipid uptake. Peroxisomes play an important role in lipid metabolism and peroxisomal targeting signal type 1 (PTS1)-containing proteins are translocated to peroxisomes by the peroxisomal targeting import receptor, Pex5p. We have previously identified a PTS1 motif in the intracellular domain of rat SR-BI. Here, we examine the possible interaction between Pex5p and SR-BI. Expression of a Flag-tagged intracellular domain of SR-BI resulted in translocation to the peroxisome as demonstrated by double labeling with anti-Flag IgG and anti-catalase IgG analyzed by confocal microscopy. Immunoprecipitation experiments with anti-SR-BI antibody showed that Pex5p co-precipitated with SR-BI. However, when an antibody against Pex5p was used for immunoprecipitation, only the 57kDa, non-glycosylated form, of SR-BI co-precipitated. We conclude that the PTS1 domain of SR-BI is functional and can mediate peroxisomal interaction via Pex5p, in vitro.
|
|
